---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-011904"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2023-07-17T23:59:59+00:00"
generated_at: "2026-06-13T07:51:34.862529+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Virios announces positive Long-COVID data for valacyclovir/celecoxib; cash $4.5M

## Summary
- Female long-COVID patients showed significant improvements in fatigue, pain, and autonomic dysfunction after 14 weeks of Val/Cel vs routine care.
- Company plans to meet with FDA in H2 2023 to discuss opening an IND for formal PASC treatment assessment.
- Treatment well tolerated; no serious adverse events; nausea most common AE in Val/Cel group.
- As of June 30, 2023, Virios had approximately $4.5M in cash and cash equivalents.

## SEC filing metadata
- accession: 0001558370-23-011904
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2023-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837023011904/0001558370-23-011904-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837023011904/tmb-20230714x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-011904
- JSON: https://secwatch.observer/filing/0001558370-23-011904.json
- Plain text: https://secwatch.observer/filing/0001558370-23-011904.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.